Novartis AG (NOVN) - Total Liabilities

Latest as of March 2026: CHF79.84 Billion CHF ≈ $100.94 Billion USD

Based on the latest financial reports, Novartis AG (NOVN) has total liabilities worth CHF79.84 Billion CHF (≈ $100.94 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Novartis AG - Total Liabilities Trend (1998–2025)

This chart illustrates how Novartis AG's total liabilities have evolved over time, based on quarterly financial data. See Novartis AG (NOVN) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Novartis AG Competitors by Total Liabilities

The table below lists competitors of Novartis AG ranked by their total liabilities.

Company Country Total Liabilities
MediaTek Inc
TW:2454
Taiwan NT$340.33 Billion
BHP Group
MX:BHPN
Mexico MX$60.55 Billion
Nestlé S.A
F:NESM
Germany €101.08 Billion
Arm Holdings plc American Depositary Shares
NASDAQ:ARM
USA $2.42 Billion
International Business Machines
NYSE:IBM
USA $123.17 Billion
Citigroup Inc.
NYSE:C
USA $2.57 Trillion
Toyota Motor Corporation
MX:TMN
Mexico MX$62.35 Trillion
Linde plc Ordinary Shares
NASDAQ:LIN
USA $47.08 Billion

Liability Composition Analysis (1998–2025)

This chart breaks down Novartis AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NOVN company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.85 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 2.07 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.67 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Novartis AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Novartis AG (1998–2025)

The table below shows the annual total liabilities of Novartis AG from 1998 to 2025.

Year Total Liabilities Change
2025-12-31 CHF68.97 Billion
≈ $87.20 Billion
+18.68%
2024-12-31 CHF58.12 Billion
≈ $73.48 Billion
+9.26%
2023-12-31 CHF53.20 Billion
≈ $67.25 Billion
-8.33%
2022-12-31 CHF58.03 Billion
≈ $73.37 Billion
-9.29%
2021-12-31 CHF63.97 Billion
≈ $80.88 Billion
-10.04%
2020-12-31 CHF71.11 Billion
≈ $89.90 Billion
+13.20%
2019-12-31 CHF62.82 Billion
≈ $79.42 Billion
-6.06%
2018-12-31 CHF66.87 Billion
≈ $84.54 Billion
+13.63%
2017-12-31 CHF58.85 Billion
≈ $74.40 Billion
+6.55%
2016-12-31 CHF55.23 Billion
≈ $69.83 Billion
+1.47%
2015-12-31 CHF54.43 Billion
≈ $68.82 Billion
-0.20%
2014-12-31 CHF54.54 Billion
≈ $68.96 Billion
+5.33%
2013-12-31 CHF51.78 Billion
≈ $65.47 Billion
-5.73%
2012-12-31 CHF54.93 Billion
≈ $69.44 Billion
+6.54%
2011-12-31 CHF51.56 Billion
≈ $65.18 Billion
-3.72%
2010-12-31 CHF53.55 Billion
≈ $67.70 Billion
+40.76%
2009-12-31 CHF38.04 Billion
≈ $48.10 Billion
+36.54%
2008-12-31 CHF27.86 Billion
≈ $35.23 Billion
+6.93%
2007-12-31 CHF26.06 Billion
≈ $32.94 Billion
-2.46%
2006-12-31 CHF26.71 Billion
≈ $33.77 Billion
+8.73%
2005-12-31 CHF24.57 Billion
≈ $31.06 Billion
+16.03%
2004-12-31 CHF21.17 Billion
≈ $26.77 Billion
+12.63%
2003-12-31 CHF18.80 Billion
≈ $23.77 Billion
+12.63%
2002-12-31 CHF16.69 Billion
≈ $21.10 Billion
+13.18%
2001-12-31 CHF14.75 Billion
≈ $18.64 Billion
+11.97%
2000-12-31 CHF13.17 Billion
≈ $16.65 Billion
-25.33%
1999-12-31 CHF17.64 Billion
≈ $22.30 Billion
-1.49%
1998-12-31 CHF17.90 Billion
≈ $22.63 Billion
--

About Novartis AG

SW:NOVN Switzerland Drug Manufacturers - General
Market Cap
$273.85 Billion
CHF216.61 Billion CHF
Market Cap Rank
#89 Global
#3 in Switzerland
Share Price
CHF113.52
Change (1 day)
+0.46%
52-Week Range
CHF91.55 - CHF130.50
All Time High
CHF130.50
About

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic … Read more